Olema Pharmaceuticals, Inc.

What they do

Olema focuses on discovering and developing next-generation targeted therapies for endocrine-driven cancers, primarily breast cancer. Its lead product candidate, palazestrant, is an orally-available small molecule with dual activity as a complete estrogen receptor antagonist and selective ER degrader, being studied in ER+/HER2- metastatic breast cancer. The company also has a second candidate, OP-3136, a KAT6 inhibitor, in Phase 1 clinical development for solid tumors.

Revenue drivers

• Palazestrant (OP-1250) — Lead candidate, no approved products or revenue yet; potential revenue from future sales if approved for ER+/HER2- metastatic breast cancer.
• OP-3136 — Second candidate, KAT6 inhibitor, in Phase 1; potential revenue from future sales if approved for solid tumors.

Recent performance

For Q2 2026, net loss was $63.2 million, up from $43.8 million in Q2 2025, due to higher R&D spending. R&D expenses were $57.8 million in Q2 2026 versus $43.9 million in the prior-year quarter. Cash, cash equivalents, and marketable securities were $461.1 million as of June 30, 2026. Enrollment in the Phase 3 OPERA-01 trial was completed, and top-line data are now expected in Q1 2027.

Strategy

Management is advancing palazestrant through late-stage clinical development as monotherapy and in combinations, including the OPERA-01 Phase 3 trial and OPERA-02 trial with ribociclib, supported by a collaboration with Novartis. They are also developing OP-3136 as a potential best-in-class KAT6 inhibitor, with a new collaboration with Bayer to evaluate it in metastatic castration-resistant prostate cancer. The company is preparing for a potential first commercial launch of palazestrant, should it gain approval.

Risks

• No approved products or revenue — The company has no products approved for commercial sale and has not generated any product revenue, making it difficult to evaluate future success.
• Dependence on clinical trial success — The company's future depends on the successful completion of Phase 3 trials (OPERA-01, OPERA-02) and positive results for palazestrant and OP-3136.
• Substantial additional capital needed — The company requires significant additional funding to finance operations; if unable to raise capital, it may delay or reduce development programs.
• Regulatory and approval uncertainties — Potential FDA approval and commercial launch depend on successful trial results and regulatory review, with expected NDA submission in 2027 and launch possibly in 2028.

Outlook

Management expects to report top-line data from the OPERA-01 Phase 3 trial in Q1 2027 and to submit an NDA in 2027, with potential FDA approval and launch in 2028. They plan to initiate a Phase 1b/2 study of OP-3136 in combination with darolutamide in mCRPC in Q4 2026, and continue advancing enrollment in OPERA-02 and the OP-3136 Phase 1 study. They are focused on preparations for the potential first commercial launch.